Old Web
English
Sign In
Acemap
>
authorDetail
>
Megan Whelan
Megan Whelan
University of Chicago
Lenalidomide
Carfilzomib
Internal medicine
Medicine
Dexamethasone
2
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).
2021
Journal of Clinical Oncology
Benjamin A. Derman
Jeffrey A. Zonder
Ankit Kansagra
David L. Grinblatt
Sunil Narula
Shayan Rayani
Andrew T. Stefka
Ken Jiang
Sarah Major
Brittany Wolfe
Megan Whelan
Bernadette Libao
Amanda McIver
Evangelia Andreatos
Daniel Juergens
Luis Alcantar
Theodore Karrison
Michael R. Bishop
Jagoda Jasielec
Andrzej Jakubowiak
Show All
Source
Cite
Save
Citations (0)
Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study
2020
Blood
Jagoda Jasielec
Jeff Zonder
Benjamin A. Derman
Donna Reece
Craig E. Cole
Jesus G. Berdeja
Brittany Wolfe
Sarah Major
Kathryn M. Tinari
Andrew T. Stefka
Fabrizio Fazzi
Megan Whelan
Christine Gleason
Amanda McIver
Evangelia Andreatos
Bernadette Libao
Daniel Juergens
Kent A. Griffith
Andrzej Jakubowiak
Show All
Source
Cite
Save
Citations (2)
1